Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 results announced for periods ended June 30, 2026.
HERON THERAPEUTICS, INC. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 results announced for periods ended June 30, 2026
- Investor-relevant financial details contained in furnished Exhibit 99.1 earnings release
- Filing indicates results availability, but provides no figures beyond the reporting periods in Item 2.02
Item EX-99.1 · Exhibit EX-99.1
- Q2 net revenue $37.7M, up 1.3% year-over-year; six-month revenue declined 4.9% to $72.4M
- Acute Care growth offset Oncology weakness: APONVIE +73.6% and ZYNRELEF +35.0%, while CINVANTI fell 9.7%
- Q2 net loss widened to $5.5M from $2.4M; Adjusted EBITDA improved to $3.2M from $2.2M
- Credit facility amendment reduces outstanding principal potentially by $17.5M, including $13.5M at execution
- Full-year 2026 guidance withdrawn amid CINVANTI generic-entry uncertainty and strategic-alternatives review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HERON THERAPEUTICS, INC. /DE/ 8-K filings
Get the next HRTX 8-K as it lands
Follow HRTX for push alerts, or ask the research agent what this filing means.